EGFR and metastatic malignant neoplasm in the spinal cord: During the follow‐up period, we observed that patients in the osimertinib cohort had a lower frequency of incident brain or spinal cord metastasis compared with patients treated with other 1L EGFR TKIs (12.8% vs. 16.2%–24.5%), which is consistent with the protective effect of osimertinib against CNS progression reported in the FLAURA trial for patients treated with osimertinib (20%) compared with patients treated with gefitinib or erlotinib (39%)31 due to osimertinib's greater penetration of the blood–brain barrier.32